The race to develop a coronavirus vaccine has already shattered records.
In March, the biotechnology company Moderna entered its vaccine candidate in a clinical trial less than 70 days after the virus was sequenced, shaving a year off the development process. Since then, two US drug companies, Moderna and Pfizer, have published early data showing that their vaccines generated immune responses without causing serious side effects.
That could put the companies on track to finish their human trials in October, under the most optimistic scenario. But scientists and public-health experts worry about the push to bring a vaccine to market before data clearly shows it’s safe and effective.
To assuage these concerns, Moderna and Pfizer — along with US pharmaceutical company Johnson & Johnson and French pharmaceutical company Sanofi — are preparing to release a joint statement that promises to put